A share price of Ascendis Pharma A/S ADR [ASND] is currently trading at $204.4, down -0.99%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ASND shares have gain 3.37% over the last week, with a monthly amount drifted -1.27%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ascendis Pharma A/S ADR [NASDAQ: ASND] stock has seen the most recent analyst activity on October 17, 2025, when Raymond James initiated its Strong Buy rating and assigned the stock a price target of $271. On May 05, 2025, upgrade upgraded it’s rating to Overweight but maintained its price target of $250 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $205 on April 16, 2025. UBS initiated its recommendation with a Buy and recommended $196 as its price target on January 07, 2025. Oppenheimer upgraded its rating to Outperform for this stock on September 05, 2024, but kept the price target unchanged to $180. In a note dated June 25, 2024, TD Cowen upgraded an Buy rating on this stock and boosted its target price from $156 to $175.
Ascendis Pharma A/S ADR experienced fluctuations in its stock price throughout the past year between $118.03 and $216.45. Currently, Wall Street analysts expect the stock to reach $242 within the next 12 months. Ascendis Pharma A/S ADR [NASDAQ: ASND] shares were valued at $204.4 at the most recent close of the market. An investor can expect a potential return of 18.4% based on the average ASND price forecast.
Analyzing the ASND fundamentals
Trailing Twelve Months sales for Ascendis Pharma A/S ADR [NASDAQ:ASND] were 720.68M which represents 292.94% growth. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.52%, Pretax Profit Margin comes in at -0.54%, and Net Profit Margin reading is -0.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is 1.87 and Total Capital is -1.66. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -4.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 198.35 points at the first support level, and at 192.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 214.88, and for the 2nd resistance point, it is at 225.35.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ascendis Pharma A/S ADR [NASDAQ:ASND] is 1.03. As well, the Quick Ratio is 0.73, while the Cash Ratio is 0.53. Considering the valuation of this stock, the price to sales ratio is 17.17.
Transactions by insiders
Recent insider trading involved JENSEN FLEMMING STEEN, Officer, that happened on Sep 09 ’25 when 5000.0 shares were purchased. Officer, JENSEN MICHAEL WOLFF completed a deal on Aug 29 ’25 to buy 5000.0 shares. Meanwhile, Officer PEDERSEN ANNI LOTTE KIRSTINE S bought 3036.0 shares on Aug 27 ’25.
